Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Trial ID or NCT#
NCT00309907
Status
NOT RECRUITING
Purpose
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
Official Title
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Eligibility Criteria
Ages Eligible for Study: 1 Year to 17 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Peds Hem/Onc CRAs
650-723-5535
View on ClinicalTrials.gov
